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Many clinical trials have been performed to evaluate if volatile anaesthetics are 
protective in scenarios of ischemia-reperfusion (I/R). While the majority of studies 
focused on I/R injury related to cardiac surgery with the use of the cardiopulmonary 
bypass,1 2 some were also performed in lung surgery with one-lung ventilation,3 liver 
resections under inflow occlusion4 as well as liver transplantation.5 The study of 
Niewuwenhuijs-Moeke and her colleagues is the first trial evaluating the direct effect 
of volatile anaesthetics on kidneys undergoing I/R injury in the process of 
transplantation (Volatile Anaesthetic Protection of Renal transplants, VAPOR-1).6 
The authors of this work have to be congratulated for their efforts. So far, only in vivo 
animal experiments have been performed7 addressing the impact of volatile 
anaesthetics on renal I/R injury, or else the kidneys were evaluated as a secondary 
outcome in clinical trials.2 Therefore, data of this study increase the knowledge and 
experience within the topic of organ protection and volatile anaesthetics.  
 
In the current study, the urinary biomarkers kidney injury marker-1 (KIM-1), N-acetyl-
β-D-glucosaminidase (NAG) and heart-type fatty acid binding protein (H-FABP) were 
defined as primary outcome6 to achieve a realistic sample size. At the same time the 
authors also evaluated clinical outcomes such as rejection rate in the two-year follow 
up after transplantation. In this three-arm study, donor and recipient couples were 
randomly assigned to a propofol group where donor and recipients were 
anaesthetized with propofol (PROP), a sevoflurane group using the same 
anaesthetic for both donor and recipient (SEVO) as well as a group with propofol 
anaesthesia for the donor and sevoflurane for the recipient (PROSE). The urinary 
markers KIM-1 and NAG were increased two days after transplantation in the SEVO 
group, glomerular filtration rate at three, six and 12 months were similar in all three 
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groups. The two-year rejection rate was significantly lower in the PROSE compared 
to the PROP group. 
 
It is certainly justified to use biomarkers as surrogates for clinical outcomes in a 
pioneering randomized controlled trial (RCT) using a small sample size. However, 
the transient differences in urinary biomarker concentrations at day two in favour of 
propofol with increased values of KIM-1 and NAG in the SEVO remains difficult to 
interpret and clinical conclusions should be avoided. Taking also the dynamic of 
urinary accumulation of biomarkers after transplantation into account, presenting 
sometimes with two peaks, makes interpretation of the current results even more 
challenging. 
 
A significant clinical finding of the VAPOR-1 trial, however, is the decreased rate of 
acute rejections in recipients after two years in the PROSE group compared to those 
in the PROP group.6 This raises the question if there is indeed a prolonged effect 
provided by intraoperative protection of volatile anaesthetics as there are studies 
suggesting that the degree of I/R injury has an effect on long-term immunological 
outcome.8 
 
It is impressive that this inaugural study could be performed in the population of living 
related kidney transplant recipients. However, it is important to realise that recipients 
of live organ donation may not represent the most vulnerable group of patients for I/R 
damage in transplantation. Donor organs from living donors are considered ideal with 
regard to function, and cold as well as warm ischemia time are generally kept as 
short as possible. As a consequence, injury may be as minimal as can be achieved 
in transplantation. Future trials should focus on scenarios of higher vulnerability such 
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as impaired donor organ function and/or increased warm ischemia time, as for 
example observed in extended criteria donor (ECD) grafts or donation after cardiac 
death (DCD) grafts, respectively. These kidneys may experience severe I/R injury. 
As a consequence, renal function is impaired and outcome is certainly less 
favourable.9 Therefore protection may be more effective. 
 
Now, what type of anaesthesia should we use for living related kidney 
transplantations based on the results of Niewuwenhuijs-Moeke’s study? Some may 
be tempted to prefer propofol due the lower kidney injury markers. Reduced rejection 
rate long term in the sevoflurane group, however, may be clinically more relevant. 
Differences in secondary outcomes may certainly lead the way to further studies. For 
sure we need future large trials to confirm results. A lot of thought has to go into the 
design of such clinical studies with increasing awareness for possible confounders, 
that small randomized trials (RCTs) may fall prey to. Improved preservation solutions, 
faster technical surgery, medication such as opioids, statins and beta blockers are 
well known to positively influence I/R injury, others are currently being defined. Depth 
of anaesthesia10 or low mean arterial pressure11 may well be new confounders, 
which impact on outcome endpoints in clinical trials of perioperative care. Such 
parameters have to be accounted for in the design of new large RCTs via strict 
protocols. 
 
It is encouraging to know that the authors of VAPOR-1 already designed a follow-up 
study, VAPOR-2 (ClinicalTrials.gov; NCT02727296). This large multicentre trial with 
more than 500 patients will compare propofol versus sevoflurane anaesthesia in 
recipients of living, DCD and donation after brain death (DBD) kidneys with the 
primary endpoint of incidence of acute rejection of the kidney allograft during one-
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year follow-up. VAPOR-1 helped to define the primary endpoint of the new trial. We 
hope that VAPOR-2 will answer the question if sevoflurane or propofol should be 
used in kidney transplantation.          
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